NYR Nyrada Inc.
—Mkt Cap: —P/E: —1d ago
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatry…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value67.63M USD
Revenue (TTM)1.39M USD
Gross Profit-828.72K USD
Net Income (TTM)-4.53M USD
Revenue/Share0.0080 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000070195
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-14.53
EV/Revenue48.66
P/S59.16
P/B11.79
EPS (TTM)-0.02
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin-59.62%
Oper. Margin-284.04%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-68.71%
ROA-62.92%
Growth
Revenue Growth-23.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.12M USD
CapEx (TTM)6.80K USD
FCF Margin-112.14%
FCF Yield—
Net Debt-5.79M USD
Net Debt/EBITDA1.24
Balance Sheet
Debt/Equity—
Current Ratio11.94
Quick Ratio11.70
Book Value/Sh0.04 AUD
Cash/Share0.03 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.258.68M
Float125.88M
Insiders45.19%
Institutions0.88%
Technical
SMA 500.6514 AUD
SMA 2000.6294 AUD
Beta1.03
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)219.89K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—